Overall rank by patents
#3,521
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Zhejiang Orient Gene Biotech Co., Ltd
USPTO PatentsView assignee record — 105 granted patents across 6 technology areas, active 2018–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES).
105
Total patents granted
6
CPC technology areas
2.7
Avg claims per patent
+5050%
5-year filing velocity
The verdict
Zhejiang holds 105 US patents across 6 technology areas — rank #3,521 of 50,000 tracked assignees.
- #3,521
- of 50,000 US assignees by volume
- Top 21%
- by Innovation Score (46.4/100)
- 2.7
- avg claims per patent
- +5050%
- filing velocity, last 5 yrs
Portfolio overview
Zhejiang Orient Gene Biotech Co., Ltd has been granted 105 US utility patents between 2018 and 2025, placing Zhejiang Orient Gene Biotech Co., Ltd at rank #3,521 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 2.7 claims per patent with primary concentration in G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES). As a Foreign Corporation, Zhejiang Orient Gene Biotech Co., Ltd is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 46.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 103 grants, compared with 2 in the 2015–2019 window — a +5050% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Zhejiang Orient Gene Biotech Co., Ltd's 2.7 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Zhejiang Orient Gene Biotech Co., Ltd against peers pursuing similar technology classes.
How does Zhejiang compare?
Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Zhejiang Orient G… ◀ 105
Zhejiang Orient Gene Biotech Co., Ltd
105 patents
What this shows Zhejiang holds 105 patents — placing it at rank #3,521 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Zhejiang's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
46 Top 21% higher than 79% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2018–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 1 | 1.0% |
| 2019 | 1 | 1.0% |
| 2020 | 2 | 1.9% |
| 2021 | 10 | 9.5% |
| 2022 | 6 | 5.7% |
| 2023 | 28 | 26.7% |
| 2024 | 36 | 34.3% |
| 2025 | 21 | 20.0% |
Which technologies does Zhejiang Orient Gene Biotech Co., Ltd patent most?
Top 6 of 6 technology areas
Patent Moat Analysis
Portfolio Volume Moderate
Tech Breadth Focused
Claim Depth Simple
Velocity Accelerating
Frequently Asked Questions
How many patents does Zhejiang Orient Gene Biotech Co., Ltd hold?
Zhejiang Orient Gene Biotech Co., Ltd holds 105 US granted patents filed between 2018 and 2025, spanning 6 technology areas.
What is Zhejiang Orient Gene Biotech Co., Ltd's Innovation Score?
Zhejiang Orient Gene Biotech Co., Ltd has an Innovation Score of 46.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Zhejiang Orient Gene Biotech Co., Ltd focus on?
Zhejiang Orient Gene Biotech Co., Ltd's top technology area is G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES) with 10 patents. The company has filed patents in 6 CPC subclasses total.
Is Zhejiang Orient Gene Biotech Co., Ltd's patent filing rate increasing or decreasing?
Zhejiang Orient Gene Biotech Co., Ltd's recent filing velocity is +5050% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Zhejiang Orient Gene Biotech Co., Ltd's patents?
Zhejiang Orient Gene Biotech Co., Ltd's patents average 2.7 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Zhejiang Orient Gene Biotech Co., Ltd patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Learn More
How to use this portfolio
Zhejiang's 105 grants land it in the top 21% by Innovation Score — but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance — Zhejiang ranks #3,521 of 50,000. Top 50 holders
- Most of this portfolio concentrates in G01N — see who else leads that technology area. G01N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
G01N technology
Zhejiang Orient Gene Biotech Co., Ltd's primary CPC class — all holders and yearly trends
Top 50 patent holders
See where Zhejiang Orient Gene Biotech Co., Ltd ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov
